Insider Trading activities of Furiex Pharmaceuticals, Inc. insiders.

Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Furiex Pharmaceuticals, Inc. since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Furiex Pharmaceuticals, Inc. since year 2005. Table 2 shows the detailed insider transactions of Furiex Pharmaceuticals, Inc. since 2005. The reporting company's ticker symbol is FURX. The reporting company's CIK number is 1484478.
The total value of stock buying since 2005 is $1,095,035,198.
The total value of stock sales since 2005 is $34,501,275.
The total value of stock option exercises since 2005 is $5,566,180.


Table 1. Monthly summaries of insider stock purchases, sales, and option exercises for Furiex Pharmaceuticals, Inc. (FURX).
Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2014-07 11,169,066 $1,061,061,270 0 $0 0 $0
2014-06 0 $0 169,544 $17,716,915 159,640 $1,784,392
2014-02 0 $0 115,113 $13,402,031 115,113 $1,477,590
2013-09 0 $0 30,000 $1,226,700 30,000 $273,300
2013-08 0 $0 7,500 $298,050 7,500 $68,325
2013-07 0 $0 10,581 $423,240 20,000 $182,200
2013-06 0 $0 385 $13,101 4,600 $41,906
2013-03 0 $0 34,179 $1,421,238 43,070 $538,216
2012-08 1,000 $18,673 0 $0 0 $0
2012-06 128,645 $2,452,239 0 $0 65,875 $600,121
2012-05 351,681 $6,675,389 0 $0 0 $0
2012-03 135,385 $3,057,396 0 $0 0 $0
2011-12 301,018 $5,214,351 0 $0 65,876 $600,130
2011-11 348,790 $5,572,230 0 $0 0 $0
2011-09 1,000 $14,950 0 $0 0 $0
2011-05 758,014 $10,968,700 0 $0 0 $0

Table 2. Detailed insider stock purchases, sales, and option exercises of Furiex Pharmaceuticals, Inc. insiders (FURX)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2014-07-02 Actavis Plc (10% Owner) Buy 11,169,066 95.00 1,061,061,270
2014-06-24 Patel Sailash (Chief Financial Officer) Sale 32,928 104.00 3,424,512
2014-06-24 Patel Sailash (Chief Financial Officer) Option Ex 32,928 9.11 299,974
2014-06-24 Covington Paul S (Senior VP-Clinical Operations) Sale 10,368 104.12 1,079,516
2014-06-24 Covington Paul S (Senior VP-Clinical Operations) Option Ex 10,368 17.80 184,550
2014-06-18 Covington Paul S (Senior VP-Clinical Operations) Sale 45,691 104.11 4,756,890
2014-06-18 Covington Paul S (Senior VP-Clinical Operations) Option Ex 45,691 9.11 416,245
2014-06-17 Mcintyre Gail Frances (Senior Vice President-Research) Sale 8,008 105.00 840,840
2014-06-17 Mcintyre Gail Frances (Senior Vice President-Research) Option Ex 8,008 13.16 105,385
2014-06-16 Mcintyre Gail Frances (Senior Vice President-Research) Sale 66,449 105.02 6,978,141
2014-06-16 Mcintyre Gail Frances (Senior Vice President-Research) Option Ex 62,645 12.42 778,238
2014-06-13 Covington Paul S (Senior VP-Clinical Operations) Sale 3,228 104.25 336,519
2014-06-10 Covington Paul S (Senior VP-Clinical Operations) Sale 2,872 104.63 300,497
2014-02-04 Almenoff June Sherie (President) Sale 115,113 116.42 13,402,031
2014-02-04 Almenoff June Sherie (President) Option Ex 115,113 12.84 1,477,590
2013-09-10 Covington Paul S (Senior VP-Clinical Operations) Sale 30,000 40.89 1,226,700
2013-09-10 Covington Paul S (Senior VP-Clinical Operations) Option Ex 30,000 9.11 273,300
2013-08-09 Corr Peter B (Director) Sale 7,500 39.74 298,050
2013-08-09 Corr Peter B (Director) Option Ex 7,500 9.11 68,325
2013-07-19 Mcintyre Gail Frances (Senior Vice President-Research) Sale 10,581 40.00 423,240
2013-07-19 Mcintyre Gail Frances (Senior Vice President-Research) Option Ex 20,000 9.11 182,200
2013-06-28 Corr Peter B (Director) Sale 385 34.03 13,101
2013-06-25 Corr Peter B (Director) Option Ex 1,000 9.11 9,110
2013-06-24 Corr Peter B (Director) Option Ex 3,600 9.11 32,796
2013-03-12 Kaldor Stephen W (Director) Sale 973 40.71 39,610
2013-03-12 Ruscher Robert P (Director) Sale 4,262 40.71 173,506
2013-03-11 Kaldor Stephen W (Director) Sale 5,379 41.74 224,519
2013-03-11 Kaldor Stephen W (Director) Option Ex 8,000 13.94 111,520
2013-03-11 Ruscher Robert P (Director) Sale 23,565 41.74 983,603
2013-03-11 Ruscher Robert P (Director) Option Ex 35,070 12.17 426,696
2012-08-15 Almenoff June Sherie (President) Buy 950 18.68 17,746
2012-08-14 Almenoff June Sherie (President) Buy 50 18.55 927
2012-06-21 Eshelman Fredric N (Director) Option Ex 65,875 9.11 600,121
2012-06-14 Eshelman Fredric N (Director) Buy 34,133 19.04 649,892
2012-06-13 Eshelman Fredric N (Director) Buy 44,193 18.33 810,057
2012-06-01 Eshelman Fredric N (Director) Buy 50,319 19.72 992,290
2012-05-31 Eshelman Fredric N (Director) Buy 70,075 20.06 1,405,704
2012-05-30 Eshelman Fredric N (Director) Buy 96,321 19.87 1,913,898
2012-05-29 Eshelman Fredric N (Director) Buy 72,431 19.96 1,445,722
2012-05-25 Eshelman Fredric N (Director) Buy 1,454 18.45 26,826
2012-05-24 Eshelman Fredric N (Director) Buy 27,000 17.99 485,729
2012-05-23 Eshelman Fredric N (Director) Buy 20,000 17.73 354,600
2012-05-22 Eshelman Fredric N (Director) Buy 35,000 16.93 592,550
2012-05-21 Eshelman Fredric N (Director) Buy 2,400 16.15 38,760
2012-05-18 Eshelman Fredric N (Director) Buy 25,000 15.28 382,000
2012-05-17 Almenoff June Sherie (President) Buy 2,000 14.80 29,600
2012-03-15 Eshelman Fredric N (Director) Buy 7,102 23.91 169,808
2012-03-14 Eshelman Fredric N (Director) Buy 22,713 23.75 539,433
2012-03-13 Eshelman Fredric N (Director) Buy 22,594 23.45 529,829
2012-03-12 Eshelman Fredric N (Director) Buy 22,351 22.69 507,144
2012-03-09 Eshelman Fredric N (Director) Buy 15,237 22.59 344,203
2012-03-08 Eshelman Fredric N (Director) Buy 14,914 22.52 335,863
2012-03-06 Eshelman Fredric N (Director) Buy 15,237 20.87 317,996
2012-03-05 Eshelman Fredric N (Director) Buy 15,237 20.55 313,120
2011-12-20 Eshelman Fredric N (Director) Option Ex 65,876 9.11 600,130
2011-12-15 Eshelman Fredric N (Director) Buy 17,359 16.88 293,019
2011-12-14 Eshelman Fredric N (Director) Buy 20,056 16.70 334,935
2011-12-13 Eshelman Fredric N (Director) Buy 94,611 17.00 1,608,387
2011-12-05 Covington Paul S (Senior VP-Clinical Operations) Buy 2,850 17.68 50,388
2011-12-05 Bondurant Stuart (Director) Buy 2,800 17.87 50,036
2011-12-05 Eshelman Fredric N (Director) Buy 110,664 17.65 1,953,219
2011-12-02 Eshelman Fredric N (Director) Buy 27,652 17.50 483,910
2011-12-01 Eshelman Fredric N (Director) Buy 25,026 17.60 440,457
2011-11-25 Eshelman Fredric N (Director) Buy 6,802 16.00 108,832
2011-11-23 Eshelman Fredric N (Director) Buy 15,278 16.22 247,809
2011-11-21 Eshelman Fredric N (Director) Buy 12,468 15.48 193,004
2011-11-18 Eshelman Fredric N (Director) Buy 23,625 15.87 374,928
2011-11-17 Mcintyre Gail Frances (Senior Vice President-Research) Buy 6,500 16.89 109,785
2011-11-10 Eshelman Fredric N (Director) Buy 12,889 16.48 212,410
2011-11-09 Eshelman Fredric N (Director) Buy 947 16.26 15,398
2011-11-08 Eshelman Fredric N (Director) Buy 250,000 16.00 4,000,000
2011-11-07 Eshelman Fredric N (Director) Buy 7,148 15.69 112,152
2011-11-04 Woodworth Marshall H (Chief Financial Officer) Buy 6,211 14.78 91,798
2011-11-04 Eshelman Fredric N (Director) Buy 6,922 15.33 106,114
2011-09-09 Almenoff June Sherie (President) Buy 1,000 14.95 14,950
2011-05-25 Eshelman Fredric N (Director) Buy 250,000 15.35 3,837,500
2011-05-24 Eshelman Fredric N (Director) Buy 14,516 14.79 214,691
2011-05-20 Eshelman Fredric N (Director) Buy 465,000 13.99 6,505,350
2011-05-19 Eshelman Fredric N (Director) Buy 12,599 14.12 177,897
2011-05-18 Eshelman Fredric N (Director) Buy 12,599 14.52 182,937
2011-05-11 Bondurant Stuart (Director) Buy 3,300 15.25 50,325

Insider trading activities including stock purchases, stock sales, and option exercises of FURX listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Furiex Pharmaceuticals, Inc. (symbol FURX, CIK number 1484478) see the Securities and Exchange Commission (SEC) website.